Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28169062 | 0.83 | CRBN (0.47) | CRBN | |
| SCHEMBL9827 | 0.83 | — | — | |
| SCHEMBL6274768 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL6065391 | 0.79 | — | — | |
| SCHEMBL3984585 | 0.79 | — | — | |
| Ammonia Solution, Strong SCHEMBL10715866 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL1650597 | 0.79 | — | — | |
| Hydrogen Sulfide SCHEMBL21461366 | 0.79 | — | — | |
| SCHEMBL10813740 | 0.79 | — | — | |
| Fluoride SCHEMBL7626958 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006331-B2 | Therapeutic compounds and methods | GENENTECH, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4370130-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11987572-B2 | Therapeutic compounds and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4362985-A1 | OLIGONUCLEOTIDE CONJUGATES TARGETED TO THE TRANSFERRIN RECEPTOR | Denali Therapeutics Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024086161-A2 | EPHA2 TARGETING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240109872-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117693367-A | Oligonucleotide conjugates targeting transferrin receptor | 戴纳立制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117642170-A | Therapeutic compounds and methods | 基因泰克公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024044375-A2 | ANTIVIRAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240051938-A1 | SELECTIVE BRD4-DEGRADER MOLECULES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-02-15 | — | — | US | disclosed |
| US-10822318-B2 | Lactone-based probes and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200339555-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2020-10-29 | — | — | US | disclosed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200308208-A1 | DINUCLEAR PLATINUM(II) COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200255454-A1 | SEPARATIONS USING BORON CONTAINING HYDROCARBON SPONGES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2019240884-A9 | COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019046465-A2 | THERAPEUTIC INDOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20180360972-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-12-20 | — | — | US | disclosed |
| US-20180339972-A1 | LACTONE-BASED PROBES AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-11-29 | — | — | US | disclosed |
| US-20180292387-A1 | ANTIBIOTIC-BASED CONJUGATES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987572-B2 | Therapeutic compounds and methods of use thereof | BRDT, BRD4, BRD3 | CRBN 1281/4885 |
| US-20180360972-A1 | THERAPEUTIC COMPOUNDS | ZFX, XPOT, HAX1 | CRBN 1754/4885 |
| US-20240051938-A1 | SELECTIVE BRD4-DEGRADER MOLECULES | BRD4, BICRA, BRD1 | CRBN 201/4885 |
| US-20180292387-A1 | ANTIBIOTIC-BASED CONJUGATES AND METHODS OF USE THEREOF | MRPL21, RDX, ABCB11 | CRBN 1577/4885 |
| US-20180339972-A1 | LACTONE-BASED PROBES AND METHODS OF USE THEREOF | MRPL21, QPCTL, ARGLU1 | CRBN 2964/4885 |
| US-20240109872-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | CYP19A1, GNRHR, NR5A1 | CRBN 3976/4885 |
| US-20200308208-A1 | DINUCLEAR PLATINUM(II) COMPOUNDS AND METHODS OF USE THEREOF | XPA, TOP2B, DCK | CRBN 604/4885 |
| US-20200339555-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | MYD88, C3AR1, FCGRT | CRBN 2345/4885 |
| US-20200255454-A1 | SEPARATIONS USING BORON CONTAINING HYDROCARBON SPONGES | BCL6B, CXCR2, CXCR1 | CRBN 765/4885 |
| US-12006331-B2 | Therapeutic compounds and methods | PCK1, SLC5A1, PFKFB1 | CRBN 4824/4885 |
| US-10822318-B2 | Lactone-based probes and methods of use thereof | MRPL21, QPCTL, ARGLU1 | CRBN 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.